Product Information
OXYBUTYNIN CL ER 5 MG TABLET is a generic product labeled by Accord Healthcare Inc., priced at $0.0841 per EA under NDC 16729031716. Its NADAC has been published 494 times since Apr 19, 2017.
FDA first approved this application on Feb 29, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Accord Healthcare Inc.NDC
16729031716
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OXYBUTYNIN CHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA207138FDA Approved
2/29/2016
TE Code
AB
On Market Since
12/14/2016
Pharmacological Classes
Price Statistics
The NADAC for OXYBUTYNIN CL ER 5 MG TABLET has been published 494 times since Apr 19, 2017, and over the history we have for it it has declined 86.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0841 per EA |
|---|---|
| All-time high | $0.6326 (Jun 14, 2017) |
| All-time low | $0.0765 (Nov 20, 2024) |
| 52-week high | $0.0990 |
| 52-week low | $0.0817 |
| Median price | $0.1571 |
| Average price | $0.2222 |
| Largest weekly change | +35.7% (Jun 19, 2024) |
| Weeks tracked | 494 |
| Tracking since | Apr 19, 2017 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 43% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Accord Healthcare Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
oxybutynin chloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Cholinergic Muscarinic Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OXYBUTYNIN CL ER 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for OXYBUTYNIN CL ER 5 MG TABLET, manufactured by Accord Healthcare Inc., is $0.0841 per EA (NDC 16729031716), effective Sep 30, 2026.
How has the price of OXYBUTYNIN CL ER 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for OXYBUTYNIN CL ER 5 MG TABLET has declined 86.6%. It has been tracked across 494 weekly CMS publications since Apr 19, 2017.
What are the highest and lowest recorded NADAC prices for OXYBUTYNIN CL ER 5 MG TABLET?
Since Apr 19, 2017, the NADAC for OXYBUTYNIN CL ER 5 MG TABLET has ranged from a low of $0.0765 (Nov 20, 2024) to a high of $0.6326 (Jun 14, 2017), with a median of $0.1571 per EA.
Are there cheaper alternatives to OXYBUTYNIN CL ER 5 MG TABLET?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OXYBUTYNIN 5 MG TABLET, is $0.0480 per EA — about 43% below OXYBUTYNIN CL ER 5 MG TABLET.
Who manufactures OXYBUTYNIN CL ER 5 MG TABLET?
OXYBUTYNIN CL ER 5 MG TABLET (NDC 16729031716) is labeled by Accord Healthcare Inc., and CMS classifies it as a generic product.